The role of time-varying viral shedding in modelling environmental surveillance for public health: revisiting the 2013 poliovirus outbreak in Israel.


Journal

Journal of the Royal Society, Interface
ISSN: 1742-5662
Titre abrégé: J R Soc Interface
Pays: England
ID NLM: 101217269

Informations de publication

Date de publication:
05 2022
Historique:
entrez: 18 5 2022
pubmed: 19 5 2022
medline: 21 5 2022
Statut: ppublish

Résumé

Environmental pathogen surveillance is a sensitive tool that can detect early-stage outbreaks, and it is being used to track poliovirus and other pathogens. However, interpretation of longitudinal environmental surveillance signals is difficult because the relationship between infection incidence and viral load in wastewater depends on time-varying shedding intensity. We developed a mathematical model of time-varying poliovirus shedding intensity consistent with expert opinion across a range of immunization states. Incorporating this shedding model into an infectious disease transmission model, we analysed quantitative, polymerase chain reaction data from seven sites during the 2013 Israeli poliovirus outbreak. Compared to a constant shedding model, our time-varying shedding model estimated a slower peak (four weeks later), with more of the population reached by a vaccination campaign before infection and a lower cumulative incidence. We also estimated the population shed virus for an average of 29 days (95% CI 28-31), longer than expert opinion had suggested for a population that was purported to have received three or more inactivated polio vaccine (IPV) doses. One explanation is that IPV may not substantially affect shedding duration. Using realistic models of time-varying shedding coupled with longitudinal environmental surveillance may improve our understanding of outbreak dynamics of poliovirus, SARS-CoV-2, or other pathogens.

Identifiants

pubmed: 35582812
doi: 10.1098/rsif.2022.0006
pmc: PMC9114981
doi:

Substances chimiques

Poliovirus Vaccine, Inactivated 0
Poliovirus Vaccine, Oral 0

Types de publication

Journal Article Research Support, U.S. Gov't, Non-P.H.S. Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

20220006

Références

Curr Opin Environ Sci Health. 2020 Oct;17:49-71
pubmed: 33024908
J Infect Dis. 2016 Aug 15;214(4):537-45
pubmed: 27190187
J Clin Virol. 2015 May;66:51-5
pubmed: 25866337
Vaccine. 1999 Mar 5;17(9-10):1084-90
pubmed: 10195618
Environ Health Perspect. 2021 Apr;129(4):45002
pubmed: 33877858
Curr Opin Biotechnol. 2008 Jun;19(3):295-301
pubmed: 18508257
Lancet Infect Dis. 2015 Nov;15(11):1273-82
pubmed: 26318714
Science. 2021 Jul 16;373(6552):
pubmed: 34083451
Science. 2021 Jul 16;373(6552):280-281
pubmed: 34437141
J Infect Dis. 2014 Nov 1;210 Suppl 1:S181-6
pubmed: 25316834
PLoS Biol. 2018 Apr 27;16(4):e2002468
pubmed: 29702638
Water Res. 2021 Sep 1;202:117438
pubmed: 34333296
Euro Surveill. 2014 Feb 20;19(7):20710
pubmed: 24576470
J Wildl Dis. 2009 Apr;45(2):512-8
pubmed: 19395763
MMWR Morb Mortal Wkly Rep. 2019 Apr 05;68(13):312-318
pubmed: 30946737
Vaccines (Basel). 2021 Aug 06;9(8):
pubmed: 34451995
Lancet. 2013 Nov 16;382(9905):1611-2
pubmed: 24238546
Euro Surveill. 2014 Feb 20;19(7):20708
pubmed: 24576473
Virus Evol. 2020 May 20;6(2):veaa040
pubmed: 32782825
J Infect Dis. 2015 Jun 1;211(11):1800-12
pubmed: 25505296
Clin Microbiol Infect. 2001;7 Suppl 2:38-45
pubmed: 11525217
Expert Rev Vaccines. 2015;14(8):1113-23
pubmed: 26159938
J Appl Microbiol. 2010 Aug;109(2):716-730
pubmed: 20233263
Euro Surveill. 2013 Sep 19;18(38):
pubmed: 24084337
Euro Surveill. 2014 Feb 20;19(7):20709
pubmed: 24576471
BMC Med. 2016 Jun 23;14(1):95
pubmed: 27334457
MMWR Morb Mortal Wkly Rep. 2017 Mar 03;66(8):227-231
pubmed: 28253229
Environ Sci Technol Lett. 2021 Apr 12;8(5):398-404
pubmed: 37566351
Nucleic Acids Res. 2003 Aug 15;31(16):e93
pubmed: 12907745
PLoS One. 2013 Jul 24;8(7):e68413
pubmed: 23894302
Risk Anal. 2013 Apr;33(4):703-49
pubmed: 23521018
J Infect Dis. 2014 Nov 1;210 Suppl 1:S173-80
pubmed: 25316833
Sci Total Environ. 2020 Oct 15;739:139076
pubmed: 32758929
Adv Appl Microbiol. 2008;65:249-69
pubmed: 19026868
Am J Trop Med Hyg. 2021 Aug 02;105(4):1004-1012
pubmed: 34339385
J Infect Dis. 2014 Nov 1;210 Suppl 1:S304-14
pubmed: 25316849
J Math Biol. 2019 Oct;79(5):1831-1883
pubmed: 31410551
Environ Sci Technol. 2021 Sep 7;55(17):11473-11475
pubmed: 34431294
Sci Transl Med. 2017 Mar 29;9(383):
pubmed: 28356510
Bioinformatics. 2009 Aug 1;25(15):1923-9
pubmed: 19505944
J Infect Dis. 2014 Nov 1;210 Suppl 1:S294-303
pubmed: 25316848
PLoS One. 2006 Dec 20;1:e69
pubmed: 17183700
J R Soc Interface. 2022 May;19(190):20220006
pubmed: 35582812
Food Environ Virol. 2017 Dec;9(4):361-382
pubmed: 28687986
Lancet Gastroenterol Hepatol. 2020 Jun;5(6):533-534
pubmed: 32246939
Appl Environ Microbiol. 2007 Sep;73(18):5954-8
pubmed: 17660306
PLoS One. 2018 Dec 28;13(12):e0208336
pubmed: 30592720
Euro Surveill. 2016 Apr 14;21(15):
pubmed: 27105043
Risk Anal. 2013 Apr;33(4):606-46
pubmed: 23550968
Proc Natl Acad Sci U S A. 2018 Nov 6;115(45):E10625-E10633
pubmed: 30337479
J Clin Microbiol. 2013 Feb;51(2):472-80
pubmed: 23175269
Lancet Infect Dis. 2014 Aug;14(8):716-724
pubmed: 25022434
Environ Sci Technol. 2021 Jul 6;55(13):8484-8491
pubmed: 34101444
BMC Infect Dis. 2018 Apr 13;18(1):176
pubmed: 29653509
Environ Sci Technol. 2020 Jul 7;54(13):7754-7757
pubmed: 32530639
J Appl Microbiol. 2012 Jan;112(1):225-37
pubmed: 22054549

Auteurs

Andrew F Brouwer (AF)

Department of Epidemiology, University of Michigan, Ann Arbor, MI, USA.

Marisa C Eisenberg (MC)

Department of Epidemiology, University of Michigan, Ann Arbor, MI, USA.

Lester M Shulman (LM)

Central Virology Laboratory, Chaim Sheba Medical Center, Tel-Hashomer, Israel.
School of Public Health, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Michael Famulare (M)

Institute for Disease Modeling, Bellevue, WA, USA.

James S Koopman (JS)

Department of Epidemiology, University of Michigan, Ann Arbor, MI, USA.

Steve J Kroiss (SJ)

Institute for Disease Modeling, Bellevue, WA, USA.

Musa Hindiyeh (M)

Central Virology Laboratory, Chaim Sheba Medical Center, Tel-Hashomer, Israel.

Yossi Manor (Y)

Central Virology Laboratory, Chaim Sheba Medical Center, Tel-Hashomer, Israel.

Itamar Grotto (I)

Ministry of Health, Jerusalem, Israel.
Department of Public Health, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel.

Joseph N S Eisenberg (JNS)

Department of Epidemiology, University of Michigan, Ann Arbor, MI, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH